FluBlok, a recombinant influenza vaccine.
Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.
Huber
Victor C
VC
St Jude Children's Research Hospital, Department of Infectious Disease, Memphis, TN 38105, USA.
McCullers
Jonathan A
JA
D000818:Animals; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics; D051379:Mice; D009975:Orthomyxoviridae / Q000276:immunology*; D010330:Patents as Topic; D013329:Structure-Activity Relationship; D019444:Vaccines, DNA / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics
C528512:FluBlok; D007252:Influenza Vaccines; D019444:Vaccines, DNA